Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has announced that it has secured market approval for its orthopaedic products in Singapore and Vietnam.
The company produces 3D-printed biomimetic and bioresorbable implants.
Osteopore said its High Tibial Osteotomy (HTO) product is the centrepiece of its expansion into Singapore and Vietnam.
It said the focus on Singapore and Vietnam enables it to leverage its existing sales and distribution channels while managing the costs associated with market expansion.
Osteopore CEO, Dr Lim Yujing, said, “We are delighted to share another positive step in the ongoing transformation of the company.
“The orthopaedic market is a high-value and high-volume segment with the HTO market expected to grow at a CAGR of 9.2%.
“These approvals enable Osteopore to supply off-the-shelf and customisable implants, positioning us to capture the potential of these high growth market segments.” said Dr Lim.